Connect Sign In
The near total automation installed in ARUP’s Automated Core Lab increases capacity for testing, provides better turnaround times, reduces risk of human error, and improves staff satisfaction.
ARUP’s International Organization for Standardization (ISO) 15189 accreditation assessment has successfully concluded, and results confirm the consistently high quality of ARUP’s operations.
A $3.6 million gift from the Miller family will enable University of Utah Health and ARUP to expand and refine testing for rare genetic disorders through the Utah NeoSeq Project.
ARUP’S new test is the first of its kind to use two distinct biomarkers to identify in utero exposure to kratom, an herbal supplement that may cause neonatal abstinence syndrome.
The Fall 2022 edition of Magnify: The Art and Science of Diagnostic Medicine, shares how ARUP has applied what it learned from COVID-19 to improve operations, services, and, ultimately, patient care.
ARUP Consult provides up-to-date guidance on test selection for the evaluation of liver function, myeloproliferative neoplasms, and hemolytic anemias.
Medical Director’s First Articles Since Coming to ARUP Offer Guidance on Monkeypox Testing Protocols
Benjamin Bradley, MD, PhD, joined ARUP’s team of medical directors amid the monkeypox outbreak. Now, his new research aims to help labs improve testing.
Tracy George, MD, has been named among Utah’s Healthcare Heroes: the leaders who have made it their goal to improve health for all Utah residents.
Group Manager Megan Flipse discusses her start as a laboratory client support technician, the completion of her medical laboratory science degree, and her career advancement at ARUP.
In September, ARUP Consult, a free informative resource in laboratory testing, released new user experience (UX) upgrades and updated several topics, including acute lymphoblastic leukemia.
The European Commission’s approval of BioMarin’s novel gene therapy for severe hemophilia A has paved the way for ARUP’s AAV5 DetectCDx™ Kit to become the first ARUP-developed test used in Europe.
Based on data from 21,916 participants in 33 studies, the Association for the Advancement of Blood and Biotherapies (AABB) has issued guidelines for use of convalescent plasma in COVID-19 treatment.
